NASDAQ:LMAT LeMaitre Vascular (LMAT) Stock Price, News & Analysis $95.40 +0.14 (+0.14%) As of 12:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About LeMaitre Vascular Stock (NASDAQ:LMAT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LeMaitre Vascular alerts:Sign Up Key Stats Today's Range$94.77▼$97.4450-Day Range$79.77▼$100.3352-Week Range$71.42▼$109.58Volume35,421 shsAverage Volume190,689 shsMarket Capitalization$2.16 billionP/E Ratio46.31Dividend Yield0.84%Price Target$97.60Consensus RatingHold Company Overview LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts. Read More LeMaitre Vascular Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreLMAT MarketRank™: LeMaitre Vascular scored higher than 38% of companies evaluated by MarketBeat, and ranked 680th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingLeMaitre Vascular has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageLeMaitre Vascular has only been the subject of 2 research reports in the past 90 days.Read more about LeMaitre Vascular's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth11.86% Earnings GrowthEarnings for LeMaitre Vascular are expected to grow by 11.86% in the coming year, from $1.94 to $2.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LeMaitre Vascular is 46.11, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.67.Price to Earnings Ratio vs. SectorThe P/E ratio of LeMaitre Vascular is 46.11, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.37.Price to Earnings Growth RatioLeMaitre Vascular has a PEG Ratio of 2.46. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLeMaitre Vascular has a P/B Ratio of 5.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about LeMaitre Vascular's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.49% of the float of LeMaitre Vascular has been sold short.Short Interest Ratio / Days to CoverLeMaitre Vascular has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in LeMaitre Vascular has recently decreased by 3.62%, indicating that investor sentiment is improving. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldLeMaitre Vascular has a dividend yield of 0.84%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthLeMaitre Vascular has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of LeMaitre Vascular is 38.83%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 36.87% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.Read more about LeMaitre Vascular's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.49% of the float of LeMaitre Vascular has been sold short.Short Interest Ratio / Days to CoverLeMaitre Vascular has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in LeMaitre Vascular has recently decreased by 3.62%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News Sentiment1.11 News SentimentLeMaitre Vascular has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for LeMaitre Vascular this week, compared to 6 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, LeMaitre Vascular insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,280,206.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of LeMaitre Vascular is held by insiders.Percentage Held by Institutions84.64% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LeMaitre Vascular's insider trading history. Receive LMAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LMAT Stock News HeadlinesJohn A. Roush Sells 939 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) StockAugust 14, 2025 | insidertrades.comLeMaitre to Participate at Upcoming Investor Conferences in SeptemberAugust 28 at 4:35 PM | globenewswire.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 29 at 2:00 AM | The Oxford Club (Ad)3 Inflated Stocks We’re Skeptical OfAugust 26 at 7:38 PM | msn.comFDA posts warning letter sent to LeMaitre over site violationsAugust 26 at 7:38 PM | msn.comBond market trumps Fed in impact on small cap stocks – Kayne Anderson RudnickAugust 25, 2025 | msn.com7 Top Trade Setups You Need to See | MSFT, LMAT, APP, IWM, ACN, BSX, UNHAugust 22, 2025 | msn.comLeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $98.00 Average Price Target from BrokeragesAugust 19, 2025 | americanbankingnews.comSee More Headlines LMAT Stock Analysis - Frequently Asked Questions How have LMAT shares performed this year? LeMaitre Vascular's stock was trading at $92.14 on January 1st, 2025. Since then, LMAT stock has increased by 3.0% and is now trading at $94.9410. How were LeMaitre Vascular's earnings last quarter? LeMaitre Vascular, Inc. (NASDAQ:LMAT) issued its earnings results on Tuesday, August, 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. The company's revenue for the quarter was up 15.0% on a year-over-year basis. Read the conference call transcript. Does LeMaitre Vascular have any subsidiaries? LeMaitre Vascular subsidiaries include these companies: Artegraft, CardioCel, Tru-Incise (Eze-Sit) US, VascuCel, LeMaitre Cardial SAS, Syntel and Python, ProCol, and others. Who are LeMaitre Vascular's major shareholders? LeMaitre Vascular's top institutional shareholders include Conestoga Capital Advisors LLC (7.10%), Copeland Capital Management LLC (4.38%), Geneva Capital Management LLC (4.05%) and State Street Corp (3.58%). Insiders that own company stock include George W Lemaitre, David B Roberts, Joseph P Pellegrino Jr, Trent G Kamke, Lawrence J Jasinski, John A Roush and Bridget A Ross. View institutional ownership trends. How do I buy shares of LeMaitre Vascular? Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LeMaitre Vascular own? Based on aggregate information from My MarketBeat watchlists, some other companies that LeMaitre Vascular investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings8/05/2025Record date for 9/4 Dividend8/21/2025Ex-Dividend for 9/4 Dividend8/21/2025Today8/29/2025Dividend Payable9/04/2025Next Earnings (Estimated)10/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LMAT CIK1158895 Webwww.lemaitre.com Phone(781) 221-2266Fax781-425-5049Employees490Year Founded1983Price Target and Rating Average Price Target for LeMaitre Vascular$97.60 High Price Target$110.00 Low Price Target$93.00 Potential Upside/Downside+2.4%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$2.06 Trailing P/E Ratio46.25 Forward P/E Ratio49.11 P/E Growth2.46Net Income$44.04 million Net Margins20.08% Pretax Margin25.95% Return on Equity13.67% Return on Assets9.14% Debt Debt-to-Equity Ratio0.46 Current Ratio13.96 Quick Ratio11.74 Sales & Book Value Annual Sales$219.86 million Price / Sales9.81 Cash Flow$2.38 per share Price / Cash Flow40.06 Book Value$16.02 per share Price / Book5.95Miscellaneous Outstanding Shares22,640,000Free Float20,487,000Market Cap$2.16 billion OptionableOptionable Beta0.79 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:LMAT) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LeMaitre Vascular, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LeMaitre Vascular With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.